Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2179)

ANNOUNCEMENT IN RELATION TO COMPLETION OF PAYMENT AND CAPITAL VERIFICATION FOR THE ISSUANCE OF DOMESTIC SHARES

References are made to the announcements dated November 11, 2024, December 24, 2024, January 9, 2025, February 27, 2025 and July 23, 2025, and the circular dated December 5, 2024 (the "**Announcements and Circular**") of Jiangsu Recbio Technology Co., Ltd. (the "**Company**") in relation to, among others, the Company's proposed issuance of Domestic Shares and the related matters, and the reply from the China Securities Regulatory Commission on issuance of Domestic Shares. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular.

For the Issuance, the Company proposes to issue 143,112,702 Domestic Shares, and the subscription price of each Share is RMB5.59, with a nominal value of RMB1.00 each. The total proceeds amounted to RMB800,000,004.00. After deducting issuance expenses related to the proceeds totaling RMB10,014,637.15 (excluding VAT), the actual net proceeds amounted to RMB789,985,366.85 (the "**Proceeds**").

The Company is pleased to announce that as of the date of this announcement, the Proceeds from the Issuance have been fully paid up and verified by a capital verification institution established under the laws of China, which has issued a capital verification report.

The Company will make further announcement(s) on the progress of the Issuance in accordance with the requirements of the Inside Information Provisions and/or the Listing Rules as and when necessary.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, October 16, 2025

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.